This session discusses the increasingly common use of NGS panels in the evaluation of patients with peripheral blood cytopenias and the utility of such panels in the diagnosis of clonal hematopoiesis of indeterminant potential (CHIP), clonal cytopenias of uncertiain significance (CCUS) and myelodysplastic syndromes (MDS).
Learning Objectives - after participation of this activity, participants will be able to:
1. Describe recurrent gene mutations identified in MDS and related conditions.
2. Assess the diagnostic yield of the AMP minimum recommended 34 core gene panel in the evaluation of patients with suspected chronic myeloid neoplasia.
3. Evaluate advantages and disadvantages of including additional genes beyond the minimum recommended 34 core gene panel.